EMD Millipore, Sysmex Collaborate on Flow Cytometry Technology Platform | GenomeWeb

NEW YORK (GenomeWeb News) – EMD Millipore today announced a clinical research, licensing, and joint development deal with Japan's Sysmex aimed at creating a flow cytometry platform for blood disorders.

The companies will use EMD Millipore's flow cytometry technology as a platform to accelerate the development of new diagnostic tools. If successful, they will then develop the platform for commercialization in the hematology space, EMD Millipore, division of Germany's Merck KGaA, said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.